Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer. [electronic resource]
Producer: 19840627Description: 241-4 p. digitalISSN:- 0277-3732
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Anthraquinones -- adverse effects
- Antineoplastic Agents -- adverse effects
- Carcinoma, Small Cell -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Drug Evaluation
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mitoxantrone
- Nausea -- chemically induced
- Neutropenia -- chemically induced
- Thrombocytopenia -- chemically induced
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.